Plasminogen Activator Inhibitor‐1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight
Jeffrey R. Holzberg(Chiricahua Community Health Centers), Miriam B. Vos(Emory University), Thomas R. Ziegler(Emory University), Craig J. McClain(University of Louisville), Ngoc‐Anh Le(Emory University), Ran Jin(Emory University), Gavin E. Arteel(University of Pittsburgh), Juna V. Konomi(Emory University), Elizabeth M. Brunt(Washington University in St. Louis)
Cited by 16
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Nonalcoholic fatty liver disease
|Nature Reviews Disease Primers|2015|832